After 14 days of treatment, the mice were euthanized via cardiac injection of sodium pentobarbitone given at 35 mg/kg
The bioavailability and absorption kinetics of AOD-9604 following administration have been studied in both preclinical and clinical research
This stepwise titration lets you monitor tolerance while gradually reaching the effective dosing levels observed in preclinical research [1] [4]
Several technical reasons may explain our distinctive findings, including differences in the microbiome sampling site, the limited n per group, singly housing mice, or the use of highly similar lean, Western, and high-fat diets which systematically exchanged fat content with carbohydrate content
Regulatory Status and Quality Control One important point often overlooked in marketing: AOD9604 is not FDAapproved for fat loss or aesthetic use
Subsequently, 1717 articles were excluded because they did not meet the inclusion criteria